Polls open in Greenland for parliamentary elections as Trump seeks control of the strategic island
Southwest is getting rid of its most recognizable perk
US airline stocks tumble as Delta's forecast cut spooks investors
Dutch marine services provider Boskalis to salvage UK ship collision tanker
Fires burn after ships collide off UK, stoking fears over environment
HOUSE VOTING ON BILL TO AVOID GOVERNMENT SHUTDOWN (4aET)
Republicans are marching ahead with a government funding bill despite Democratic opposition
Korean Air launches new branding after $1.3 billion Asiana acquisition
Air France-KLM offers 300 million euros for 51% in Air Europa, El Confidencial reports
Health|Political
Trump's FDA nominee tepidly backs role for vaccine advisers in guarded Senate appearance
Martin Makary, President Donald Trump's nominee to run the U.S.
Latest From Michael Erman
Health|Political|US
Kennedy proposes scrapping public comment on major US health policies
U.S. Secretary of Health and Human Services Robert F.
Health|Political|Science|US
Meeting of US FDA vaccine advisers canceled, committee member says
A meeting of a committee which advises the U.S.
Business|Health|Political|Science|Technology|US
US FDA asks fired scientists to return, including some reviewing Musk’s Neuralink
The U.S.
Business|Economy|Health|Political|Technology
Trump is firing federal workers who are not funded by taxpayers
Elon Musk's DOGE team has slashed hundreds of jobs paid for by fees from banks, medical device companies and other forms of funding
Economy|Environment|Health|Political|Science
Trump cuts could clash with Kennedy's long to-do list
Robert F.
Business|Economy|Finance|Health|Stock Markets|US
Bristol Myers forecasts steeper drop in 2025 revenue, shares fall
Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its
Business|Economy|Health|Political|US
Trump faces pressure from US industry over China tariff on medicines
President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new tariffs on Chinese imports,
Business|Economy|Finance|Health|Stock Markets
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors
Asia|Business|Economy|Health|Stock Markets
Merck stops Gardasil shipments to China, hitting 2025 outlook; shares tumble
Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move
Business|Economy|Health|US
Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S.
Health|Political|US
Opponents of Kennedy's bid for top US health post urge senators to reject him
More than 80 organizations voiced opposition on Friday to Robert F.
Business|Finance|Health|News|US
Pharma industry to get US government price cut proposals by Thursday
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in
Business|Finance|Health|US
Drugmakers sign on to negotiate Medicare prices under protest
All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S.
Business|Health|US
US plans shift of Merck COVID treatment to commercial market
The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on
Health|US
New COVID shots still hard to find for some Americans
Americans have started rolling up their sleeves for the latest version of the COVID-19 vaccine, but weeks into the rollout some
Business|Finance|Health|Stock Markets
Merck 3rd-quarter profit tops expectations on COVID pill surprise
Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for its COVID-19 treatment, primarily in Japan.
Business|Health|US
Bristol Myers says it needs another year to hit target for new drugs
Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new
Business|Health|News
Pfizer RSV vaccine lags GSK’s as head-to-head competition underway
Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead
Business|Finance|Health
Pfizer looks beyond COVID after quarterly loss on Paxlovid charge
Pfizer on Tuesday urged investors to focus on growth in non-COVID products such as the new RSV vaccine Abrysvo as slumping demand for COVID-19 vaccines
Business|Finance|Stock Markets
Pfizer shares sink after it resets 2024 COVID expectations
Pfizer on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, a move top executives said provided a more
Business|Health|News|US
Merck posts better-than-expected quarterly results on soaring Keytruda sales
Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling
Business|Finance|Health|Stock Markets|US
Bristol Myers posts better-than-expected 4th-quarter results
Drugmaker Bristol Myers Squibb on Friday posted better-than-expected results for the fourth quarter as sales of its new anemia drug Reblozyl and its already off patent
Business|News|Science|Technology|US
Exclusive-China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators
U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi
Health|Science|World
What are the FLiRT COVID variants and are they more contagious?
The so-called FLiRT variants of SARS-CoV-2 coronavirus that cause COVID-19 have been the dominant forms of the virus circulating this year globally, according to
